Cardiovascular Systems, Inc. (CSII) Hit 12-Month High at $33.68

June 27, 2018 - By Gregory Tomko

During Q1 2018 the big money sentiment decreased to 0.86. That’s change of 0.16, from 2017Q4’s 1.02. 17 investors sold all, 42 reduced holdings as Cardiovascular Systems, Inc. ratio worsened. 34 grew holdings while 17 funds bought holdings. Funds hold 26.24 million shares thus 0.31% more from 2017Q4’s 26.16 million shares.
Bluemountain Management holds 0.02% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 43,249 shs. Partner Inv Mngmt Lp has invested 0.2% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Millennium Mngmt Ltd Liability has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). United Automobile Association reported 92,298 shs stake. Panagora Asset Management owns 40,714 shs. D E Shaw & Co reported 0.02% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Pura Vida Invs Limited Liability has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 67,000 shs. Glenmede Trust Na reported 0% stake. Morgan Stanley holds 190,733 shs or 0% of its capital. First Foundation Advsr holds 16,175 shs. Gamco Invsts Et Al holds 88,500 shs or 0.01% of its capital. Citadel Limited Co has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). Howe Rusling Inc has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Granahan Investment Mgmt Ma accumulated 289,014 shs. Mairs And Power has invested 0.02% in Cardiovascular Systems, Inc. (NASDAQ:CSII).

A one-year high was broke into by Cardiovascular Systems, Inc. (NASDAQ:CSII). Today’s stock price was $33.68. It’s 4.00 % above our $35.02. On Jun, 27 it was announced by The company has $1.12 billion MC. $44.80 million more could be NASDAQ:CSII valuation at $35.02 share price.

CSII is hitting $33.675 during the last trading session, after increased 9.41%.Cardiovascular Systems, Inc. is uptrending after having risen 0.43% since June 27, 2017. CSII has 295,464 volume or 38.30% up from normal. CSII underperformed the S&P 500 by 12.14%.

Cardiovascular Systems, Inc. (NASDAQ:CSII) is awaited to reveal earnings on August, 1., according to Zacks. Last year’s EPS was $0.02, while now analysts expect change of 200.00 % up from current $0.06 EPS. If reported the P/E will be 140.31 with $2.00M profit. After $0.01 EPS report last quarter, Wall Street now predicts 500.00 % EPS growth of Cardiovascular Systems, Inc..

More recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were released by, and The first one has “BofA/Merrill Lynch Double Upgrades Cardiovascular Systems (CSII) to Buy” as a title and was released on June 27, 2018. The next is “Detailed Research: Economic Perspectives on LSC Communications, Cardiovascular, RPX, Nustar Energy, LSB …” on June 19, 2018. And last was released on June 27, 2018, called “Cardiovascular Systems gets two-notch upgrade at BAML”.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States.The firm is worth $1.12 billion. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.Last it reported negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.